Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Kaitlyn M Logan und 37 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States. Hauptthemen laut MEDLINE: Indazoles, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Protein Kinase Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Inhibition of leucine-rich repeat kinase 2 is a genetically supported mechanism for the treatment of Parkinson's disease. We previously disclosed the discovery of an indazole series lead that demonstrated both safety and translational risks. The safety risks were hypothesized to be of unknown origin, so structural diversity in subsequent chemical matter was prioritized. The translational risks were identified due to a low brain Kpu,u in nonhuman primate studies, which raised concern over the use of an established peripheral biomarker as a surrogate for central target engagement. Given these challenges, the team sought to leverage structure- and property-based drug design and expanded efflux transporter profiling to identify structurally distinct leads with enhanced CNS drug-likeness. Herein, we describe the discovery of a "reinvented" indazole series with improved physicochemical properties and efflux transporter profiles while maintaining excellent potency and off-target kinase selectivity, which resulted in advanced lead, compound 23.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States.
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, New Jersey 07065, United States.
- Evotec (U.K.) Ltd., 90 Park Drive, Milton Park, Abingdon OX14 4RZ, Oxfordshire, U.K.
ORCID-Profile: Kaitlyn M Logan, Mitchell H Keylor, Solomon D Kattar, Spencer E McMinn, Santhosh F Neelamkavil, Lily Y Moy, Erin F DiMauro
Zitieren
APA
Logan, K. M., Kaplan, W., Simov, V., Zhou, H., Li, D., Torres, L., Morriello, G. J., Acton, J. J., Pio, B., Chen, Y. H., Keylor, M. H., Johnson, R., Kattar, S. D., Chau, R., Yan, X., Ardolino, M., Zarate, C., Otte, K. M., Palte, R. L., …, & Fuller, P. H. (2024). Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01627
Vancouver
Logan KM, Kaplan W, Simov V, Zhou H, Li D, Torres L, et al. Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01627
BibTeX
@article{Logan2024,
author = {Logan, Kaitlyn M and Kaplan, Will and Simov, Vladimir and Zhou, Hua and Li, Derun and Torres, Luis and Morriello, Gregori J and Acton, John J and Pio, Barbara and Chen, Yi-Heng and Keylor, Mitchell H and Johnson, Rebecca and Kattar, Solomon D and Chau, Ryan and Yan, Xin and Ardolino, Michael and Zarate, Cayetana and Otte, Karin M and Palte, Rachel L and Xiong, Tina and McMinn, Spencer E and Lin, Shishi and Neelamkavil, Santhosh F and Liu, Ping and Su, Jing and Hegde, Laxminarayan G and Woodhouse, Janice D and Moy, Lily Y and Ciaccio, Paul J and Piesvaux, Jennifer and Zebisch, Matthias and Henry, Clare and Barker, John and Wood, Harold B and Kennedy, Matthew E and DiMauro, Erin F and Fell, Matthew J and Fuller, Peter H},
title = {Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01627}
}
EUVIMED